A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants

NCT06973005 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Chronic Liver Disease
Healthy Participants

Interventions

DRUG: AZD2389
DRUG: Midazolam
DRUG: Caffeine
DRUG: Bupropion

Sponsor

AstraZeneca

Collaborators

[object Object]